胸腺五肽联合同步放化疗治疗中晚期食管癌的临床疗效观察  

The clinical observation of thymopentin combined with radiotherapy and chemotherapy in medium and advanced esophageal patients

作　　者：苏先旭[1] 王辉[1] 黄鑫[2] 李涛[3] 

机构地区：[1]都江堰市人民医院肿瘤科,四川都江堰611830 [2]广西医科大学附属肿瘤医院放疗科,广西南宁530021 [3]四川省肿瘤医院放疗科,四川成都610041

出　　处：《四川医学》2013年第5期626-629,共4页Sichuan Medical Journal

摘　　要：目的观察胸腺五肽(TP-5)联合同步放化疗治疗中晚期食管癌的近期疗效、不良反应、生活质量的改变。方法将88例中晚期食管癌患者随机分为治疗组(46例)和对照组(42例),两组皆采用同步放化疗,治疗组在对照组基础上同时加用TP-5治疗。结果治疗组和对照组近期疗效分别为82.6%、76.2%,差异无统计学意义(P>0.05),治疗组的生活质量改善率较对照组差异有统计学意义(P<0.05),且治疗组的不良反应发生率低于对照组,1、2、3年生存率分别为63.0%、41.3%、21.7%和45.2%、21.4%、19.0%(P均<0.05)。结论 TP-5联合同步放化疗治疗中晚期食管癌可获得较好近期疗效,并能减轻放化疗不良反应的发生率,改善了患者的生活质量,增加患者治疗顺应性和耐受性,值得在临床上进一步推广应用。Objective To observe the short-term efficacy,adverse reactions and change of life quality of advanced esophageal carcinoma with thymopentin （ TP-5） plus concurrent chemoradiotherapy. Methods A total of 88 patients with advanced esophageal carcinoma were randomly divided into treatment group（ 46 patients） group and control group（ 32 patients）,Both groups received concurrent radiochemotherapy,The treatment group also received add-on TP-5 therapy. Results The short-term efficacy of treatment group and control group were 82. 6% and 76. 2%,they have no statistic significance（ P0. 05） . The change of life patients’life qualities between the two groups were significantly difference（ P0. 05）,and the treatment group’s side effects incidence rate was lower than the control group,The 1-,2-and 3-year overall survival rates were 63. 0% 、41. 3% 、21. 7% VS 45. 2% 、 21. 4% 、19. 0% （ P0. 05） . Conclusion The TP-5 combined with concurrent chemoradiotherapy had a better effect in the esophageal patients,reduced the side effects and improved the patients’life qualities,increase patients compliance and tolerance,deserved to be used in the clinical furtherly.

关 键 词：食管癌 胸腺五肽 同步放化疗 免疫治疗 

分 类 号：R735.1[医药卫生—肿瘤]